$CHEV
Charging Robotics Inc. Stock $chev

$chev Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000121390024021834 Filed on March 12, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$227.0K	$437.0K
YoY Change		327.72%
% of Gross Profit
Research & Development	$9.000K	$303.0K
YoY Change		-55.57%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$236.0K	$740.0K
YoY Change		624.29%
Operating Profit		-$740.0K
YoY Change		624.29%
Interest Expense	-$14.00K	-$3.000K
YoY Change		-160.0%
% of Operating Profit
Other Income/Expense, Net		$28.00K
YoY Change
Pretax Income	-$250.0K	-$778.0K
YoY Change		661.1%
Income Tax
% Of Pretax Income
Net Earnings	-$250.0K	-$778.0K
YoY Change		661.08%
Net Earnings / Revenue
Basic Earnings Per Share		$0.00
Diluted Earnings Per Share	-$0.03	$0.00
COMMON SHARES
Basic Shares Outstanding	1.373B shares	996.3M shares	256.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.000K	$8.000K
YoY Change		-92.53%
Cash & Equivalents	$8.000K		$107.1K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$51.00K	$51.00K	$107.1K
YoY Change	-52.36%	-52.36%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$100.0K		$74.00K
YoY Change	35.14%		0.0%
Long-Term Investments	$110.0K	$110.0K
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$272.0K	$272.0K	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$51.00K	$51.00K	$107.1K
Total Long-Term Assets	$272.0K	$272.0K	$0.00
Total Assets	$323.0K	$323.0K	$107.1K
YoY Change	201.69%	201.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$104.0K	$202.0K	$52.14K
YoY Change	99.45%	266.34%	176.52%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$30.00K	$30.00K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$348.0K	$348.0K	$55.14K
YoY Change	531.08%	531.12%	192.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$49.00K	$49.00K
YoY Change
Total Long-Term Liabilities	$49.00K	$49.00K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$348.0K	$348.0K	$55.14K
Total Long-Term Liabilities	$49.00K	$49.00K
Total Liabilities	$397.0K	$397.0K	$55.14K
YoY Change	619.93%	619.99%	192.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.966M		-$1.660M
YoY Change	18.45%		6.56%
Common Stock	$137.0K		$31.44K
YoY Change	335.74%		22.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$74.00K	-$74.00K	$51.92K
YoY Change
Total Liabilities & Shareholders Equity	$323.0K	$323.0K	$107.1K
YoY Change	201.69%	201.7%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$250.0K	-$778.0K
YoY Change		661.08%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$106.0K	-$617.0K
YoY Change		835.76%
INVESTING ACTIVITIES
Capital Expenditures	$26.00K	$26.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$3.000K
YoY Change
Cash From Investing Activities	-$26.00K	-$23.00K
YoY Change		-63.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	30.00K	$621.0K
YoY Change		258.96%
NET CHANGE
Cash From Operating Activities	-106.0K	-$617.0K
Cash From Investing Activities	-26.00K	-$23.00K
Cash From Financing Activities	30.00K	$621.0K
Net Change In Cash	-102.0K	-$19.00K
YoY Change		-117.75%
FREE CASH FLOW
Cash From Operating Activities	-$106.0K	-$617.0K
Capital Expenditures	$26.00K	$26.00K
Free Cash Flow	-$132.0K	-$643.0K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-56253
CY2023	dei	Entity Registrant Name EntityRegistrantName	FUEL DOCTOR HOLDINGS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2274999
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	20 Raul Wallenberg Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Tel Aviv
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6971916
CY2023	dei	City Area Code CityAreaCode	(678)
CY2023	dei	Local Phone Number LocalPhoneNumber	558-5564
CY2023	dei	Security12b Title Security12bTitle	None
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	133000000	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1372656029	shares
CY2023	dei	Auditor Name AuditorName	Elkana Amitai CPA
CY2023	dei	Auditor Location AuditorLocation	Mitzpe Netofa, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	43000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	71000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	51000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	98000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	110000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	152000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	100000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	74000	usd
CY2023Q4	fdoc	Shareholder Loan ShareholderLoan	62000	usd
CY2022Q4	fdoc	Shareholder Loan ShareholderLoan	60000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	272000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	286000	usd
CY2023Q4	us-gaap	Assets Assets	323000	usd
CY2022Q4	us-gaap	Assets Assets	384000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	104000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	108000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	116000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	30000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	348000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	703000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	49000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	49000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	397000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	752000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2990000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1372656029	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1372656029	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2990000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27273	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27273	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	137000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1681000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	741000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-27000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-12000	usd
CY2023Q4	fdoc	Reserve From Sharebased Compensation Transactions ReserveFromSharebasedCompensationTransactions	101000	usd
CY2022Q4	fdoc	Reserve From Sharebased Compensation Transactions ReserveFromSharebasedCompensationTransactions	91000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1966000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1188000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-74000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-368000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	323000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	384000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	303000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	682000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	437000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	71000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	740000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	753000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-740000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-753000	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	11000	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	15000	usd
CY2023	fdoc	Share In Losses Of Affiliate ShareInLossesOfAffiliate	-27000	usd
CY2022	fdoc	Share In Losses Of Affiliate ShareInLossesOfAffiliate	-42000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-778000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-810000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-15000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-23000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-793000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-833000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-30.54
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	996282214	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27273	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	450000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-833000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-368000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-368000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	91000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	10000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	509000	usd
CY2023	fdoc	Stock Issued During Period Value Reverse Effect Of Reverse Merger StockIssuedDuringPeriodValueReverseEffectOfReverseMerger	-24000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	501000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-793000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-74000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-778000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-810000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	10000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	15000	usd
CY2023	fdoc	Share In Losses Of Affiliates ShareInLossesOfAffiliates	27000	usd
CY2022	fdoc	Share In Losses Of Affiliates ShareInLossesOfAffiliates	42000	usd
CY2022	us-gaap	Interest Expense InterestExpense	5000	usd
CY2023	us-gaap	Interest Expense InterestExpense	-3000	usd
CY2023	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-28000	usd
CY2022	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	31000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-52000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-69000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	93000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	116000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	25000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	49000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-617000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-612000	usd
CY2023	fdoc	Effect Of Reverses Merger EffectOfReversesMerger	3000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	26000	usd
CY2022	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	3000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	60000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-63000	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	500000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	91000	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	30000	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	535000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	621000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	535000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-140000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	3000	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	65000	usd
CY2023	fdoc	Decrease In Related Party Balances DecreaseInRelatedPartyBalances	40000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	137000	usd
CY2023	fdoc	Decrease In Additional Paid In Capital DecreaseInAdditionalPaidInCapital	159000	usd
CY2023	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	509000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	921750000	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	921750000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	922500000	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	136500000	shares
CY2023Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	500000	usd
CY2023Q4	us-gaap	Noncash Project Abandonment Costs NoncashProjectAbandonmentCosts	445000	usd
CY2023Q4	fdoc	Finance Percentage FinancePercentage	0.50	pure
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b. Use of estimates, assumptions and judgements:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company’s management believes that the estimates, judgment and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amount of expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Warrants and options </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company uses the Black-Scholes option-pricing model to estimate the fair value of options at the grant date, and the warrant liability at the grant date and each reporting period date. The key assumptions used in the model are the expected future volatility in the price of the Company’s shares and the expected life of the warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Income Taxes</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the final outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Intangible assets</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Intangible assets are tested for impairment annually or more frequently if there is an indication of impairment. The carrying value of intangibles with definite lives is reviewed each reporting period to determine whether there is any indication of impairment. If there are indications of impairment the impairment analysis is completed and if the carrying amount of an asset exceeds its recoverable amount, the asset is impaired and impairment loss is recognized.</p>
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.50	pure
CY2023Q4	us-gaap	Grants Receivable GrantsReceivable	77000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1188000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1966000	usd
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.1999	pure
CY2022Q3	us-gaap	Participating Mortgage Loans Participation Liabilities Amount ParticipatingMortgageLoansParticipationLiabilitiesAmount	1000000	usd
CY2023Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	62000	usd
CY2021Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	217000	usd
CY2022	fdoc	Share In Loss Of Affiliates ShareInLossOfAffiliates	-42000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-23000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	152000	usd
CY2023	fdoc	Share In Loss Of Affiliates ShareInLossOfAffiliates	-27000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-15000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	110000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P20Y
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	74000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	74000	usd
CY2023	fdoc	Intangible Assetsof Additions IntangibleAssetsofAdditions	26000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	100000	usd
CY2023Q2	us-gaap	Loans Payable LoansPayable	553000	usd
CY2023Q2	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	28	shares
CY2023	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	55000	usd
CY2021Q4	fdoc	Related Party Fee Expense RelatedPartyFeeExpense	24700	ils
CY2021Q4	fdoc	Related Party Fee Expense RelatedPartyFeeExpense	7000	usd
CY2021Q4	fdoc	Stock Options Percentage StockOptionsPercentage	0.03	pure
CY2021Q4	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10000000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2990000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023	fdoc	Percentage Of Shares Issued And Outstanding PercentageOfSharesIssuedAndOutstanding	0.7288	pure
CY2023Q2	fdoc	Number Of Shares NumberOfShares	15	shares
CY2023Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	91000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	28	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	7636	shares
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	501000	usd
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	(i) change its name to Charging Robotics Inc. (the “Name Change”); and (ii) effect a one-for-one hundred and fifty reverse stock split (the “Reverse Stock Split”) of its outstanding shares of Common Stock.
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	922500000	shares
CY2022Q1	fdoc	Stock Options Granted StockOptionsGranted	30000	usd
CY2023Q4	us-gaap	Share Price SharePrice	7410
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0048	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.75	pure
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8333
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6818
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8333
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	18	shares
CY2023	fdoc	Estimated Sale Of Years EstimatedSaleOfYears	P3Y
CY2023	fdoc	Percentage Of Three Years Sales PercentageOfThreeYearsSales	0.03	pure
CY2023	fdoc	Percentage Fourth Fifth And Sixth Years Of Sales PercentageFourthFifthAndSixthYearsOfSales	0.04	pure
CY2023	fdoc	Percentage Of Seventh Years Of Sales PercentageOfSeventhYearsOfSales	0.05	pure
CY2023	fdoc	Percentage Of Grants Received PercentageOfGrantsReceived	1	pure
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	303000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	682000	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	390000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	67000	usd
CY2023	us-gaap	Other Expenses OtherExpenses	28000	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	19000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	4000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	437000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	71000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	905000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	489000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	905000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	489000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	905000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	489000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	905000	usd
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	6816
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties		usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2022	fdoc	Effect Of Reverses Merger EffectOfReversesMerger		usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2023	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits		usd
CY2022	fdoc	Intangible Assetsof Additions IntangibleAssetsofAdditions		usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber		shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
CY2023Q4	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount		usd
CY2022	us-gaap	Other Expenses OtherExpenses		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001459188
CY2023	dei	No Trading Symbol Flag NoTradingSymbolFlag	true

Files In Submission

Name	View Source	Status
0001213900-24-021834-index-headers.html	Edgar Link	pending
0001213900-24-021834-index.html	Edgar Link	pending
0001213900-24-021834.txt	Edgar Link	pending
0001213900-24-021834-xbrl.zip	Edgar Link	pending
ea0200626-10k_fueldoctor.htm	Edgar Link	pending
ea020062601ex21-1_fuel.htm	Edgar Link	pending
ea020062601ex31-1_fuel.htm	Edgar Link	pending
ea020062601ex31-2_fuel.htm	Edgar Link	pending
ea020062601ex32-1_fuel.htm	Edgar Link	pending
ea020062601ex32-2_fuel.htm	Edgar Link	pending
ea020062601ex4-1_fuel.htm	Edgar Link	pending
fdoc-20231231.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
fdoc-20231231_cal.xml	Edgar Link	unprocessable
fdoc-20231231_def.xml	Edgar Link	unprocessable
fdoc-20231231_lab.xml	Edgar Link	unprocessable
fdoc-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0200626-10k_fueldoctor_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CHEV
Charging Robotics Inc. Stock $chev

2023 Q4 Form 10-K Financial Statement

#000121390024021834 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHEV Charging Robotics Inc. Stock $chev

2023 Q4 Form 10-K Financial Statement

#000121390024021834 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CHEV
Charging Robotics Inc. Stock $chev